Still, mAbs possess many drawbacks, such as a lack of oral bioavailability or poor permeability of tumor tissues, which leads to the overall low response rate of PD-1/PD-L1 inhibition that limits their clinical effectiveness. Here, PDCD1 is linked to neoplasm.